As of 2025-06-30, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -0.50. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 67.93 mil USD. NKTR's TTM EBITDA according to its financial statements is -136.65 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 12.7x | 10.4x |
| Forward P/E multiples | 10.9x - 17.3x | 14.4x |
| Fair Price | (350.46) - (409.77) | (400.87) |
| Upside | -1460.5% - -1690.7% | -1656.2% |
| Date | EV/EBITDA |
| 2025-06-27 | -0.50 |
| 2025-06-26 | -0.62 |
| 2025-06-25 | -0.60 |
| 2025-06-24 | -0.46 |
| 2025-06-23 | -0.00 |
| 2025-06-20 | 0.03 |
| 2025-06-18 | 0.02 |
| 2025-06-17 | 0.02 |
| 2025-06-16 | 0.00 |
| 2025-06-13 | 0.02 |
| 2025-06-12 | 0.02 |
| 2025-06-11 | -0.01 |
| 2025-06-10 | -0.06 |
| 2025-06-09 | 0.02 |
| 2025-06-06 | -0.02 |
| 2025-06-05 | -0.02 |
| 2025-06-04 | -0.06 |
| 2025-06-03 | -0.06 |
| 2025-06-02 | -0.08 |
| 2025-05-30 | -0.05 |
| 2025-05-29 | -0.05 |
| 2025-05-28 | -0.03 |
| 2025-05-27 | -0.02 |
| 2025-05-23 | -0.01 |
| 2025-05-22 | -0.02 |
| 2025-05-21 | -0.00 |
| 2025-05-20 | -0.03 |
| 2025-05-19 | -0.03 |
| 2025-05-16 | -0.03 |
| 2025-05-15 | -0.02 |
| 2025-05-14 | -0.04 |
| 2025-05-13 | -0.04 |
| 2025-05-12 | -0.04 |
| 2025-05-09 | 0.02 |
| 2025-05-08 | 0.00 |
| 2025-05-07 | 0.01 |
| 2025-05-06 | -0.01 |
| 2025-05-05 | -0.03 |
| 2025-05-02 | -0.06 |
| 2025-05-01 | -0.07 |
| 2025-04-30 | -0.08 |
| 2025-04-29 | -0.05 |
| 2025-04-28 | -0.06 |
| 2025-04-25 | -0.07 |
| 2025-04-24 | -0.05 |
| 2025-04-23 | -0.03 |
| 2025-04-22 | -0.02 |
| 2025-04-21 | -0.00 |
| 2025-04-17 | -0.01 |
| 2025-04-16 | 0.01 |